Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$97.63 +1.38%

+$1.21 today

Market cap
$9.27B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 0.63M

Average 1.17M

Balance Sheet

Inspect the capital base behind the business.

Assets

$777.78M

FY 2025 · Annual

+27.8% YoY

Liabilities

$62.55M

FY 2025 · Annual

-31.0% YoY

Equity

$715.24M

FY 2025 · Annual

+38.1% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.14M34.86M188.89M89.42M85.72M
Short-term Investments77.99M20.85M150.38M513.67M670.81M
Net Receivables815K375K000
Inventory00000
Other Current Assets06.17M2.25M5.39M21.25M
Total Current Assets98.89M62.26M341.53M608.47M777.78M
Property, Plant & Equipment (Net)8.36M6.65M000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.68M2.24M331K10K0
Total Non-current Assets11.04M8.89M331K10K0
Total Assets109.93M71.14M341.86M608.48M777.78M
Account Payables3.32M677K896K666K8.9M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.36M517K000
Other Current Liabilities4.99M4.92M5.93M31.27M30.94M
Total Current Liabilities20.14M14.66M31.98M54.06M58.69M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.22M2.18M000
Other Non-current Liabilities00125.87M36.62M3.86M
Total Non-current Liabilities5.84M6.18M125.87M36.62M3.86M
Total Liabilities25.99M20.84M157.84M90.68M62.55M
Common Stock5K6K10K13K15K
Retained Earnings(341.81M)(425.62M)(764.41M)(972.43M)(1.13B)
Accumulated OCI(20K)(48K)302K180K869K
Other Stockholders Equity00000
Minority Interest00000
Total Equity83.94M50.31M184.02M517.8M715.24M
Total Debt5.06M4.63M000
Net Debt(10.08M)(30.23M)(188.89M)(89.42M)(85.72M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$82.7M
Short-term Investments$989.2M
Other Current$27.8M
Total Current Assets$1.1B
Total Assets$1.1B

Analysis

Selected assets total $1.1B for Latest. The largest visible component is Short-term Investments at $989.2M, about 89.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 3, 2026
8-KCurrent reportNov 3, 2026
SC 13D/ASC 13D/A filingOct 9, 2026
8-KCurrent reportOct 7, 2026
424B5424B5 filingOct 6, 2026

How much cash does SYRE have?

Spyre Therapeutics, Inc. (SYRE) reported $85.72M in cash and equivalents in fiscal 2025.

How much debt does SYRE carry?

Spyre Therapeutics, Inc. (SYRE) reported $0.00 of total debt, with net debt of -$85.72M.